Anna Antonell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3969412/publications.pdf

Version: 2024-02-01

101	5,087	109321	98798
papers	citations	35 h-index	67 g-index

108	108	108	8082
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	12.4	600
2	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	6.9	392
3	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
4	A Panâ€<scp>E</scp>uropean Study of theC9orf72Repeat Associated with<scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	2.5	247
5	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Annals of Neurology, 2013, 74, 655-668.	5.3	171
6	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
7	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
8	Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology, 2011, 76, 1720-1725.	1.1	123
9	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 2014, 127, 407-418.	7.7	123
10	Identification of blood serum microâ€RNAs associated with idiopathic and LRRK2 Parkinson's disease. Journal of Neuroscience Research, 2014, 92, 1071-1077.	2.9	122
11	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimerâ€™s Disease: Potential and Limitations. Molecular Neurobiology, 2017, 54, 5550-5562.	4.0	119
12	Hemizygosity at the NCF1 Gene in Patients with Williams-Beuren Syndrome Decreases Their Risk of Hypertension. American Journal of Human Genetics, 2006, 78, 533-542.	6.2	107
13	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A largeâ€scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315.	0.8	104
14	Partial 7q11.23 deletions further implicate GTF2I and GTF2IRD1 as the main genes responsible for the Williams-Beuren syndrome neurocognitive profile. Journal of Medical Genetics, 2010, 47, 312-320.	3.2	103
15	Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 901-908.	2.6	102
16	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Human Molecular Genetics, 2014, 23, 749-754.	2.9	98
17	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
18	Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid ÃŸ-Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas. Biological Psychiatry, 2011, 70, 183-190.	1.3	93

#	Article	IF	Citations
19	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 444.e1-444.e4.	3.1	92
20	A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1772-1778.	3.1	87
21	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid Î² protein 42 levels. Neurobiology of Aging, 2014, 35, 2671-2680.	3.1	72
22	Evolutionary mechanisms shaping the genomic structure of the Williams-Beuren syndrome chromosomal region at human 7q11.23. Genome Research, 2005, 15, 1179-1188.	5.5	70
23	Distinct Functional Activity of the Precuneus and Posterior Cingulate Cortex During Encoding in the Preclinical Stage of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 517-526.	2.6	59
24	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiology of Aging, 2016, 38, 47-55.	3.1	54
25	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 113.	6.2	54
26	Neuroimaging and Biochemical Markers in the Three Variants of Primary Progressive Aphasia. Dementia and Geriatric Cognitive Disorders, 2013, 35, 106-117.	1.5	53
27	The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. Journal of Alzheimer's Disease, 2013, 36, 67-77.	2.6	53
28	Different profiles of Alzheimerâ€™s disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. Journal of Neural Transmission, 2011, 118, 259-262.	2.8	49
29	Copathology in Progressive Supranuclear Palsy: Does It Matter?. Movement Disorders, 2020, 35, 984-993.	3.9	48
30	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47
31	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer's and Dementia, 2020, 16, 262-272.	0.8	47
32	CSF microRNA Profiling in Alzheimerâ€™s Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	4.0	45
33	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
34	Cognitive Reserve Proxies Relate to Gray Matter Loss in Cognitively Healthy Elderly with Abnormal Cerebrospinal Fluid Amyloid-Î² Levels. Journal of Alzheimer's Disease, 2013, 35, 715-726.	2.6	40
35	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. International Journal of Geriatric Psychiatry, 2012, 27, 127-134.	2.7	38
36	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Neurodegenerative Diseases, 2016, 16, 69-76.	1.4	36

#	Article	IF	Citations
37	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	3.1	35
38	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	4.2	33
39	Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2014, 40, 919-927.	2.6	32
40	MAPT H1 Haplotype is Associated with Late-Onset Alzheimerâ€™s Disease Risk in APOE É›4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	2.6	32
41	Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort. Journal of Alzheimer's Disease, 2012, 31, 581-591.	2.6	31
42	Frontotemporal Dementia Caused by the P301L Mutation in the<i> MAPT</i> Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. Dementia and Geriatric Cognitive Disorders, 2017, 44, 213-221.	1.5	31
43	Evolving brain structural changes in PSEN1 mutation carriers. Neurobiology of Aging, 2015, 36, 1261-1270.	3.1	30
44	Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. NeuroImage: Clinical, 2019, 23, 101927.	2.7	29
45	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimer's and Dementia, 2020, 16, 292-304.	0.8	29
46	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
47	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimerâ€™s disease. NeuroImage: Clinical, 2021, 32, 102804.	2.7	28
48	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
49	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. Neuropathology and Applied Neurobiology, 2015, 41, 882-892.	3.2	26
50	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
51	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease Families with <i>PSEN1</i> Mutations. Neurodegenerative Diseases, 2011, 8, 202-207.	1.4	24
52	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
53	Contribution of CSF biomarkers to earlyâ€onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. Human Brain Mapping, 2020, 41, 2004-2013.	3.6	22
54	The hippocampal longitudinal axisâ€”relevance for underlying tau and TDP-43 pathology. Neurobiology of Aging, 2018, 70, 1-9.	3.1	21

#	Article	IF	Citations
55	Clinical applicability of diagnostic biomarkers in earlyâ€onset cognitive impairment. European Journal of Neurology, 2019, 26, 1098-1104.	3.3	20
56	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Research - Neuroimaging, 2011, 192, 140-146.	1.8	19
57	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
58	Evolving Brain Functional Abnormalities in PSEN1 Mutation Carriers: A Resting and Visual Encoding fMRI Study. Journal of Alzheimer's Disease, 2013, 36, 165-175.	2.6	19
59	Phenotypic Variability Within the Inclusion Body Spectrum of Basophilic Inclusion Body Disease and Neuronal Intermediate Filament Inclusion Disease in Frontotemporal Lobar Degenerations With FUS-Positive Inclusions. Journal of Neuropathology and Experimental Neurology, 2012, 71, 795-805.	1.7	18
60	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. Journal of Neuropathology and Experimental Neurology, 2018, 77, 703-709.	1.7	18
61	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 827-835.	2.6	17
62	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 5902-5911.	4.0	15
63	MAPT gene duplications are not a cause of frontotemporal lobar degeneration. Neuroscience Letters, 2007, 424, 61-65.	2.1	14
64	Transcriptome profile in Williamsâ€“Beuren syndrome lymphoblast cells reveals gene pathways implicated in glucose intolerance and visuospatial construction deficits. Human Genetics, 2010, 128, 27-37.	3.8	14
65	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. Neuroscience Letters, 2011, 496, 40-42.	2.1	13
66	Cellular crosstalk between TNF-Î±, NADPH oxidase, PKCÎ²2, and C2GNT in human leukocytes. Cellular Signalling, 2012, 24, 873-878.	3.6	13
67	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	3.7	13
68	Large APP locus duplication in a sporadic case of cerebral haemorrhage. Neurogenetics, 2014, 15, 145-149.	1.4	12
69	Diagnostic Accuracy of MRI Visual Rating Scales in the Diagnosis of Early Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 73, 1575-1583.	2.6	12
70	Decreased striatal dopamine transporter uptake in the nonâ€fluent/agrammatic variant of primary progressive aphasia. European Journal of Neurology, 2013, 20, 1459.	3.3	11
71	Screening of dementia genes by whole-exome sequencing in Spanish patients with early-onset dementia: likely pathogenic, uncertain significance and risk variants. Neurobiology of Aging, 2020, 93, e1-e9.	3.1	11
72	Breakpoint Sequence Analysis of an AÎ²PP Locus Duplication Associated with Autosomal Dominant Alzheimer's Disease and Severe Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2012, 28, 303-308.	2.6	10

#	Article	IF	Citations
73	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. Brain Pathology, 2021, 31, e12942.	4.1	9
74	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimerâ€™s Disease Traits. Frontiers in Aging Neuroscience, 2020, 12, 622360.	3.4	9
75	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	3.1	8
76	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	2.7	8
77	A unique common ancestor introduced P301L mutation in MAPT gene in frontotemporal dementia patients from Barcelona (Baix Llobregat, Spain). Neurobiology of Aging, 2019, 84, 236.e9-236.e15.	3.1	7
78	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811.	7.6	7
79	PSEN1 Mutation Carriers Present Lower Cerebrospinal Fluid Amyoid-Î²42 Levels than Sporadic Early-Onset Alzheimer's Disease Patients but no Differences in Neuronal Injury Biomarkers. Journal of Alzheimer's Disease, 2012, 30, 605-616.	2.6	6
80	Novel P397S MAPT variant associated with late onset and slow progressive frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 1559-1565.	3.7	6
81	Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimerâ€™s disease. Journal of Neurology, 2022, 269, 2573-2583.	3.6	6
82	Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. Neurobiology of Aging, 2016, 46, 169-179.	3.1	5
83	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2017, 56, 1065-1074.	2.6	5
84	Regional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers. Neurobiology of Aging, 2019, 81, 1-8.	3.1	5
85	Evolution of Clinical-Pathological Correlations in Early-Onset Alzheimerâ€™s Disease Over a 25-Year Period in an Academic Brain Bank. Journal of Alzheimer's Disease, 2022, 87, 1659-1669.	2.6	5
86	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
87	Distinct neuropsychological presentation and progression between earlyâ€•and lateâ€•onset Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e036809.	0.8	1
88	An ABCA7 partial deletion and a GRN variant in a semantic variant of primary progressive aphasia patient. Alzheimer's and Dementia, 2020, 16, e042483.	0.8	1
89	Reply. Annals of Neurology, 2014, 75, 460-461.	5.3	0
90	P1-253: WHITE MATTER CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE: AN MRI DIFFUSION TENSOR IMAGING STUDY. , 2014, 10, P399-P400.		0

#	Article	IF	Citations
91	[P2â€“410]: VISUAL AND QUANTITATIVE ASSESSMENT OF HIPPOCAMPAL ATROPHY IN EARLY ONSET ALZHEIMER's DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P789.	0.8	0
92	P2â€347: THE HIPPOCAMPAL LONGITUDINAL AXIS: RELEVANCE FOR UNDERLYING TAU AND TDPâ€43 PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P819.	0.8	0
93	P1â€146: WHOLE EXOME SEQUENCING IN PATIENTS WITH EARLYâ€ONSET ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA: MUTATION DETECTION IN CAUSAL AND RISK GENES FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P332.	0.8	0
94	P1â€432: REGIONAL PATTERNS OF 18Fâ€FLORBETABEN UPTAKE IN PRESENILIN 1ÂMUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P475.	0.8	0
95	O3â€09â€03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1037.	0.8	0
96	ICâ€02â€05: GENDER DIFFERENCES IN THE ASSOCIATION BETWEEN LONGITUDINAL BRAIN CHANGES AND BASELINE LEVELS OF CSF ALZHEIMER'S DISEASE AND GLIAL BIOMARKERS IN HEALTHY ELDERS. Alzheimer's and Dementia, 2019, 15, P4.	0.8	0
97	Four yearsâ€™ experience in an earlyâ€onset dementia clinic in Barcelona. Alzheimer's and Dementia, 2020, 16, e037911.	0.8	0
98	Differential gene expression in genetic and earlyâ€onset Alzheimerâ€™s disease in two biological samples: Brain tissue and lymphoblastoid cell lines. Alzheimer's and Dementia, 2020, 16, e042671.	0.8	0
99	Functional network alterations in earlyâ€onset Alzheimerâ€™s disease studied with restingâ€state fMRI. Alzheimer's and Dementia, 2020, 16, e043307.	0.8	0
100	Agreement of amyloid PET and CSF biomarkers in a clinical cohort. Alzheimer's and Dementia, 2021, 17, .	0.8	0
101	Impact of COVIDâ€19 pandemic in an earlyâ€onset dementia clinic in Barcelona. Alzheimer's and Dementia, 2021, 17, e052114.	0.8	0